Af­ter a 6-month romp, Arie Bellde­grun and David Chang fly a $100M-plus IPO for off-the-shelf CAR-T play­er Al­lo­gene

Back in ear­ly April, Arie Bellde­grun and David Chang were just get­ting start­ed when they rolled out news of a $300 mil­lion round for a start­up com­pa­ny called Al­lo­gene and their deal to take over Pfiz­er’s R&D group and pipeline fo­cused on de­vel­op­ing the world’s first off-the-shelf CAR-Ts.

An­oth­er $120 mil­lion flowed in just a few days ago.

Along the way, the crew found time to write an S-1 with $100 mil­lion pen­ciled in for the next raise, look­ing to take the fund­ing past a half bil­lion dol­lars in 6 months time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER